\-\ Texto\\:\\ \ \(0\)\
\-\ radiation\\ therapy\\ is\\ the\\ usual\\ treatment\\ for\\ symptomatic\\ metastatic\\ prostate\\ disease\\,\\ but\\ current\\ research\\ is\\ directed\\ at\\ the\\ utilization\\ of\\ bisphosphonates\\.\\ these\\ drugs\\ inhibit\\ bone\\ resorption\\ as\\ well\\ as\\ modify\\ the\\ microenvironment\\,\\ thus\\ making\\ tumor\\ growth\\ less\\ favorable\\ \\(eaton\\ and\\ coleman\\)\\.\ \(0\)\
\-\ tc99m\\ mcp\\ bone\\ scan\\ \\(posterior\\ view\\)\\ show\\ multiple\\ areas\\ of\\ increased\\ radiopharmaceutical\\ uptake\\ in\\ the\\ spine\\ and\\ in\\ the\\ left\\ posterior\\ sixth\\ rib\\ consistent\\ with\\ metastases\\ from\\ the\\ patient\\‚\\Ä\\ôs\\ prostate\\ cancer\\.\ \(0\)\
\-\ axial\\ ct\\ images\\ \\(bone\\ windows\\)\\ of\\ the\\ chest\\ at\\ the\\ level\\ of\\ the\\ sixth\\ rib\\ shows\\ pathologic\\ fracture\\ through\\ osteolytic\\ mass\\ of\\ the\\ left\\ posterior\\ rib\\ with\\ associated\\ pleural\\ reaction\\.\\ \ \(0\)\
\-\ axial\\ ct\\ images\\ of\\ the\\ chest\\ \\(bone\\ windows\\)\\ also\\ show\\ osteosclerotic\\ and\\ osteolytic\\ metastases\\ of\\ the\\ thoracic\\ spine\\.\\ \\ \ \(0\)\
\-\ p\\-a\\ radiograph\\ shows\\ pathological\\ fracture\\ through\\ osteolytic\\ lesion\\ of\\ the\\ left\\ posterior\\ sixth\\ rib\\ consistent\\ with\\ osteolytic\\ metastasis\\ from\\ patient\\‚\\Ä\\ôs\\ prostate\\ cancer\\.\ \(0\)\
\-\ metastatic\\ prostate\\ cancer\ \(4\)\
\-\ metastases\\ from\\ prostate\\ cancer\ \(2\)\
\-\ or\\ rarely\\ metastases\\ from\\ other\\ cancers\\ \\(lung\\,urinary\\ bladder\\)\ \(1\)\
\-\ paget\\‚\\Ä\\ôs\\ disease\\ \ \(0\)\
\-\ lymphoma\ \(373\)\
\-\ 73\\-year\\-old\\ man\\ with\\ recently\\ diagnosed\\ prostate\\ cancer\\ presents\\ with\\ back\\ pain\\ and\\ acute\\ onset\\ of\\ left\\-sided\\ pleuritic\\ chest\\ pain\\.\ \(1\)\
\-\ prostate\\ cancer\\ typically\\ presents\\ after\\ the\\ age\\ of\\ 50\\ years\\ and\\ once\\ a\\ patient\\ in\\ the\\ united\\ states\\ reaches\\ this\\ age\\,\\ his\\ chance\\ for\\ developing\\ prostate\\ cancer\\ increases\\ with\\ each\\ decade\\ until\\ age\\ 90\\.\\ ethnicity\\ also\\ plays\\ a\\ factor\\ with\\ the\\ incidence\\ of\\ black\\ men\\ at\\ 137\\/100\\,000\\ and\\ white\\ men\\ at\\ 101\\/100\\,000\\ \\(boyle\\ et\\ al\\)\\.\\ \\ the\\ usual\\ site\\ for\\ metastases\\ is\\ the\\ spine\\ due\\ to\\ metastatic\\ cells\\ traveling\\ via\\ batson\\‚\\Ä\\ôs\\ plexus\\ of\\ veins\\.\\ however\\,\\ its\\ location\\ in\\ comparison\\ to\\ the\\ prostate\\ is\\ not\\ the\\ only\\ reason\\ for\\ metastatic\\ disease\\ developing\\ in\\ the\\ spine\\.\\ according\\ to\\ eaton\\ and\\ coleman\\ prostate\\ cancer\\ has\\ a\\ predilection\\ for\\ bone\\ over\\ other\\ tissues\\ due\\ to\\ \\‚\\Ä\\úselective\\ adherence\\,\\‚\\Ä\\ù\\ in\\ which\\ prostatic\\ cancer\\ cell\\‚\\Ä\\ôs\\ surface\\ molecules\\ bind\\ to\\ collagen\\ derived\\ from\\ bone\\ matrix\\.\\ this\\ is\\ also\\ why\\ prostate\\ metastases\\ can\\ be\\ found\\ in\\ other\\ bones\\ throughout\\ the\\ skeleton\\.\\ once\\ located\\ there\\,\\ the\\ tumor\\ will\\ find\\ an\\ environment\\ well\\ suited\\ for\\ growth\\ due\\ to\\ the\\ abundance\\ of\\ growth\\ factors\\ \\(berruti\\ et\\ al\\)\\.\\ \ \(0\)\
\-\ while\\ it\\ is\\ well\\ known\\ that\\ prostate\\ metastases\\ are\\ osteosclerotic\\,\\ it\\ is\\ unusual\\ for\\ osteolytic\\ lesions\\ to\\ be\\ present\\.\\ while\\ the\\ pathogenesis\\ is\\ still\\ largely\\ unknown\\,\\ osteosclerotic\\ and\\ osteolytic\\ lesions\\ seem\\ to\\ develop\\ due\\ the\\ interplay\\ between\\ different\\ growth\\ factors\\ located\\ in\\ bone\\ and\\ the\\ tumor\\ cells\\ themselves\\.\\ interleukin\\ 6\\,\\ tumor\\ necrosis\\ factor\\,\\ and\\ parathyroid\\ hormone\\ related\\ peptide\\ for\\ osteolytic\\ lesions\\ and\\ transforming\\ growth\\ factor\\ and\\ fibroblastic\\ growth\\ factor\\ for\\ osteosclerotic\\ \\(berruti\\ et\\ al\\)\\.\\ \ \(0\)\
\-\ the\\ imaging\\ workup\\ for\\ metastatic\\ prostate\\ cancer\\ begins\\ with\\ a\\ bone\\ scan\\,\\ which\\ has\\ largely\\ replaced\\ the\\ skeletal\\ survey\\.\\ according\\ to\\ manyak\\ et\\ al\\ a\\ bone\\ scan\\ detects\\ bone\\ metastases\\ in\\ 25\\%\\ of\\ patients\\ with\\ a\\ normal\\ skeletal\\ survey\\.\\ in\\ a\\ positive\\ skeletal\\ survey\\,\\ 50\\%\\ of\\ bone\\ marrow\\ must\\ be\\ replaced\\ by\\ metastases\\,\\ where\\ only\\ 10\\%\\ of\\ marrow\\ needs\\ replacement\\ for\\ a\\ bone\\ scan\\ to\\ be\\ positive\\ \\(wilkinson\\ and\\ hamdy\\)\\.\\ however\\,\\ radiographs\\ are\\ still\\ helpful\\ when\\ evaluating\\ osteosclerotic\\ metastases\\ in\\ order\\ to\\ differentiate\\ these\\ lesions\\ from\\ osteoarthritis\\,\\ which\\ is\\ also\\ common\\ in\\ the\\ elderly\\ male\\ patient\\ and\\ can\\ produce\\ a\\ positive\\ bone\\ scan\\ but\\ usually\\ in\\ the\\ periarticular\\ areas\\.\\ \ \(0\)\
\-\ references\\:\ \(0\)\
\-\ berruti\\ a\\,\\ dogliotti\\ l\\,\\ tucci\\ m\\,\\ tarabuzzi\\ r\\,\\ fontana\\ d\\,\\ angeli\\ a\\.\\ metabolic\\ bone\\ disease\\ induced\\ by\\ prostate\\ cancer\\:\\ rationale\\ for\\ the\\ use\\ of\\ bisphosphonates\\.\\ j\\ urol\\.\\ 2001\\ dec\\;166\\(6\\)\\:2023\\-31\\.\ \(0\)\
\-\ boyle\\ p\\,\\ severi\\ g\\,\\ giles\\ gg\\.\\ the\\ epidemiology\\ of\\ prostate\\ cancer\\.\\ urol\\ clin\\ north\\ am\\.\\ 2003\\ may\\;30\\(2\\)\\:209\\-17\\.\ \(0\)\
\-\ eaton\\ cl\\ and\\ coleman\\ re\\.\\ pathophysiology\\ of\\ bone\\ metastases\\ from\\ prostate\\ cancer\\ and\\ the\\ role\\ of\\ bisphosphonates\\ in\\ treatment\\.\\ \\ cancer\\ treat\\ rev\\.\\ 2003\\ jun\\;29\\(3\\)\\:189\\-98\\.\ \(0\)\
\-\ manyak\\ mj\\,\\ javitt\\ m\\,\\ kang\\ ps\\,\\ kreuger\\ wr\\,\\ storm\\ es\\.\\ the\\ evolution\\ of\\ imaging\\ in\\ advanced\\ prostate\\ cancer\\.\\ urol\\ clin\\ north\\ am\\.\\ 2006\\ may\\;33\\(2\\)\\:133\\-46\\,\\ v\\.\ \(0\)\
\-\ wilkinson\\,\\ ba\\,\\ hamdy\\,\\ fc\\.\\ state\\-of\\-the\\-art\\ staging\\ in\\ prostate\\ cancer\\.\\ bju\\ int\\.\\ 2001\\ mar\\;87\\(5\\)\\:423\\-30\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ prostate\\:\\ 0\\.10651804627002344\ \(0\)\
\-\ cancer\\:\\ 0\\.05860057917840449\ \(0\)\
\-\ osteolytic\\:\\ 0\\.05266880300352219\ \(0\)\
\-\ metastases\\:\\ 0\\.052357310235297036\ \(0\)\
\-\ osteosclerotic\\:\\ 0\\.04843040458179014\ \(0\)\
\-\ bone\\:\\ 0\\.04152740576518651\ \(0\)\
\-\ eaton\\:\\ 0\\.03448051534797848\ \(0\)\
\-\ coleman\\:\\ 0\\.03448051534797848\ \(0\)\
\-\ berruti\\:\\ 0\\.03448051534797848\ \(0\)\
\-\ growth\\:\\ 0\\.029066378066302214\ \(0\)\
\-\ urol\\:\\ 0\\.029058242749074085\ \(0\)\
\-\ bisphosphonates\\:\\ 0\\.025101524711218234\ \(0\)\
\-\ boyle\\:\\ 0\\.022987010231985655\ \(0\)\
\-\ manyak\\:\\ 0\\.022987010231985655\ \(0\)\
\-\ hamdy\\:\\ 0\\.022987010231985655\ \(0\)\
\-\ factor\\:\\ 0\\.022744047602153795\ \(0\)\
\-\ rib\\:\\ 0\\.022280175445614052\ \(0\)\
\-\ sixth\\:\\ 0\\.02205005708064623\ \(0\)\
\-\ wilkinson\\:\\ 0\\.021179586032350855\ \(0\)\
\-\ survey\\:\\ 0\\.0205743299705753\ \(0\)\
\-\ al\\:\\ 0\\.018892107291141005\ \(0\)\
\-\ et\\:\\ 0\\.018239365998030152\ \(0\)\
\-\ \\‚\\Ä\\ô\\:\\ 0\\.016649457233673115\ \(0\)\
\-\ skeletal\\:\\ 0\\.016507425973266918\ \(0\)\
\-\ s\\:\\ 0\\.015976321167630946\ \(0\)\
\-\ scan\\:\\ 0\\.015594989963709118\ \(0\)\
\-\ north\\:\\ 0\\.014811014884060883\ \(0\)\
\-\ spine\\:\\ 0\\.014675898545008333\ \(0\)\
\-\ largely\\:\\ 0\\.01449132173649287\ \(0\)\
\-\ replaced\\:\\ 0\\.014392911494034339\ \(0\)\
\-\ metastatic\\:\\ 0\\.014022877468162259\ \(0\)\
\-\ windows\\:\\ 0\\.01357131815207894\ \(0\)\
\-\ \\;\\:\\ 0\\.0132035279560143\ \(0\)\
\-\ \\(\\:\\ 0\\.013185220557254297\ \(0\)\
\-\ clin\\:\\ 0\\.013119501408209222\ \(0\)\
\-\ \\)\\:\\ 0\\.013024156049004264\ \(0\)\
\-\ usual\\:\\ 0\\.013003590684426084\ \(0\)\
\-\ men\\:\\ 0\\.01258548729439954\ \(0\)\
\-\ according\\:\\ 0\\.01239915362039134\ \(0\)\
\-\ lesions\\:\\ 0\\.011929911375978866\ \(0\)\
\-\ due\\:\\ 0\\.011891927785933974\ \(0\)\
\-\ 2001\\:\\ 0\\.011835338474447048\ \(0\)\
\-\ developing\\:\\ 0\\.011660268584388041\ \(0\)\
\-\ from\\:\\ 0\\.011558083431655132\ \(0\)\
\-\ m\\:\\ 0\\.011496216888402203\ \(0\)\
\-\ modify\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ microenvironment\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ 137\\/100\\,000\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ 101\\/100\\,000\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ interleukin\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ transforming\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ dogliotti\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ tucci\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ tarabuzzi\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ fontana\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ angeli\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ \\:2023\\-31\\.\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ severi\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ giles\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ \\:209\\-17\\.\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ \\:189\\-98\\.\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ javitt\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ kreuger\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ \\:133\\-46\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ state\\-of\\-the\\-art\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ \\:423\\-30\\:\\ 0\\.011493505115992828\ \(0\)\
\-\ am\\:\\ 0\\.011464609690143155\ \(0\)\
\-\ for\\:\\ 0\\.011407167905753041\ \(0\)\
\-\ once\\:\\ 0\\.011402521949090434\ \(0\)\
\-\ 2003\\:\\ 0\\.011196166484791284\ \(0\)\
\-\ \\,\\:\\ 0\\.0109413455424197\ \(0\)\
\-\ positive\\:\\ 0\\.010845706350524578\ \(0\)\
\-\ still\\:\\ 0\\.010614305855549538\ \(0\)\
\-\ p\\-a\\:\\ 0\\.010589793016175427\ \(0\)\
\-\ 73\\-year\\-old\\:\\ 0\\.010589793016175427\ \(0\)\
\-\ ethnicity\\:\\ 0\\.010589793016175427\ \(0\)\
\-\ suited\\:\\ 0\\.010589793016175427\ \(0\)\
\-\ abundance\\:\\ 0\\.010589793016175427\ \(0\)\
\-\ interplay\\:\\ 0\\.010589793016175427\ \(0\)\
\-\ rationale\\:\\ 0\\.010589793016175427\ \(0\)\
\-\ kang\\:\\ 0\\.010589793016175427\ \(0\)\
\-\ bju\\:\\ 0\\.010589793016175427\ \(0\)\
\-\ tumor\\:\\ 0\\.010389738209182849\ \(0\)\
\-\ posterior\\:\\ 0\\.010271908989321765\ \(0\)\
\-\ age\\:\\ 0\\.010173052120773038\ \(0\)\
\-\ inhibit\\:\\ 0\\.010061155326334274\ \(0\)\
\-\ batson\\:\\ 0\\.010061155326334274\ \(0\)\
\-\ adherence\\:\\ 0\\.010061155326334274\ \(0\)\
\-\ peptide\\:\\ 0\\.010061155326334274\ \(0\)\
\-\ detects\\:\\ 0\\.010061155326334274\ \(0\)\
\-\ 166\\:\\ 0\\.010061155326334274\ \(0\)\
\-\ ps\\:\\ 0\\.010061155326334274\ \(0\)\
\-\ ba\\:\\ 0\\.010061155326334274\ \(0\)\
\-\ fc\\:\\ 0\\.010061155326334274\ \(0\)\
\-\ factors\\:\\ 0\\.010009868791514795\ \(0\)\
\-\ marrow\\:\\ 0\\.009802536163280808\ \(0\)\
\-\ utilization\\:\\ 0\\.009686080916358027\ \(0\)\
\-\ 90\\.\\:\\ 0\\.009686080916358027\ \(0\)\
\-\ molecules\\:\\ 0\\.009686080916358027\ \(0\)\
\-\ bind\\:\\ 0\\.009686080916358027\ \(0\)\
\-\ gg\\:\\ 0\\.009686080916358027\ \(0\)\
\-\ fibroblastic\\:\\ 0\\.009395150601737155\ \(0\)\
\-\ re\\:\\ 0\\.009395150601737155\ \(0\)\
\-\ wr\\:\\ 0\\.009395150601737155\ \(0\)\
\-\ storm\\:\\ 0\\.009395150601737155\ \(0\)\
\-\ es\\:\\ 0\\.009395150601737155\ \(0\)\
\-\ located\\:\\ 0\\.00917131957605857\ \(0\)\
\-\ jun\\:\\ 0\\.009157443226516874\ \(0\)\
\-\ mj\\:\\ 0\\.009157443226516874\ \(0\)\
\-\ cells\\:\\ 0\\.008934671953455013\ \(0\)\
\-\ in\\:\\ 0\\.008790554996406883\ \(0\)\
\-\ also\\:\\ 0\\.008785499836610958\ \(0\)\
\-\ rev\\:\\ 0\\.008782368816540629\ \(0\)\
\-\ plays\\:\\ 0\\.008628805536675721\ \(0\)\
\-\ environment\\:\\ 0\\.008628805536675721\ \(0\)\
\-\ 50\\:\\ 0\\.008477178661391927\ \(0\)\
\-\ themselves\\:\\ 0\\.00836717490373941\ \(0\)\
\-\ int\\:\\ 0\\.00836717490373941\ \(0\)\
\-\ mar\\:\\ 0\\.00836717490373941\ \(0\)\
\-\ reaches\\:\\ 0\\.008253731126699476\ \(0\)\
\-\ v\\.\\:\\ 0\\.008253731126699476\ \(0\)\
\-\ traveling\\:\\ 0\\.008149372968063834\ \(0\)\
\-\ prostatic\\:\\ 0\\.008052752404630038\ \(0\)\
\-\ derived\\:\\ 0\\.008052752404630038\ \(0\)\
\-\ seem\\:\\ 0\\.008052752404630038\ \(0\)\
\-\ epidemiology\\:\\ 0\\.008052752404630038\ \(0\)\
\-\ chest\\:\\ 0\\.007997636245335797\ \(0\)\
\-\ tc99m\\:\\ 0\\.007962800812078601\ \(0\)\
\-\ radiopharmaceutical\\:\\ 0\\.007799615488800889\ \(0\)\
\-\ pleuritic\\:\\ 0\\.007799615488800889\ \(0\)\
\-\ why\\:\\ 0\\.007799615488800889\ \(0\)\
\-\ \\%\\:\\ 0\\.007796562060023498\ \(0\)\
\-\ other\\:\\ 0\\.007703931741991325\ \(0\)\
\-\ selective\\:\\ 0\\.00765460162294662\ \(0\)\
\-\ pathogenesis\\:\\ 0\\.00765460162294662\ \(0\)\
\-\ 87\\:\\ 0\\.007587726402102356\ \(0\)\
\-\ well\\:\\ 0\\.007560942449681817\ \(0\)\
\-\ research\\:\\ 0\\.0075241147147888845\ \(0\)\
\-\ periarticular\\:\\ 0\\.0075241147147888845\ \(0\)\
\-\ cl\\:\\ 0\\.0075241147147888845\ \(0\)\
\-\ evolution\\:\\ 0\\.0075241147147888845\ \(0\)\
\-\ areas\\:\\ 0\\.007497645818112299\ \(0\)\
\-\ pathophysiology\\:\\ 0\\.00746346280392201\ \(0\)\
\-\ predilection\\:\\ 0\\.007350019026882076\ \(0\)\
\-\ dec\\:\\ 0\\.007350019026882076\ \(0\)\
\-\ chance\\:\\ 0\\.0072967960874814825\ \(0\)\
\-\ find\\:\\ 0\\.0072967960874814825\ \(0\)\
\-\ disease\\:\\ 0\\.007284159276222707\ \(0\)\
\-\ favorable\\:\\ 0\\.007245660868246435\ \(0\)\
\-\ mcp\\:\\ 0\\.007245660868246435\ \(0\)\
\-\ resorption\\:\\ 0\\.0071032889100130685\ \(0\)\
\-\ parathyroid\\:\\ 0\\.007059088712261202\ \(0\)\
\-\ needs\\:\\ 0\\.007059088712261202\ \(0\)\
\-\ reason\\:\\ 0\\.007016337965425491\ \(0\)\
\-\ while\\:\\ 0\\.007010819399875654\ \(0\)\
\-\ begins\\:\\ 0\\.006934825114080857\ \(0\)\
\-\ be\\:\\ 0\\.006872264528521143\ \(0\)\
\-\ united\\:\\ 0\\.006858109990191766\ \(0\)\
\-\ show\\:\\ 0\\.006840041550173731\ \(0\)\
\-\ skeleton\\:\\ 0\\.0068213813370409234\ \(0\)\
\-\ cancers\\:\\ 0\\.006717023178405283\ \(0\)\
\-\ only\\:\\ 0\\.0066999000221249945\ \(0\)\
\-\ induced\\:\\ 0\\.006684014302284956\ \(0\)\
\-\ 6\\:\\ 0\\.006654811372555082\ \(0\)\
\-\ directed\\:\\ 0\\.0066518205440185005\ \(0\)\
\-\ is\\:\\ 0\\.006597936121854668\ \(0\)\
\-\ g\\:\\ 0\\.006589724000355848\ \(0\)\
\-\ role\\:\\ 0\\.006589724000355848\ \(0\)\
\-\ decade\\:\\ 0\\.006559750704104611\ \(0\)\
\-\ differentiate\\:\\ 0\\.006559750704104611\ \(0\)\
\-\ elderly\\:\\ 0\\.006559750704104611\ \(0\)\
\-\ increases\\:\\ 0\\.006530451022420051\ \(0\)\
\-\ pathological\\:\\ 0\\.006501795342213042\ \(0\)\
\-\ black\\:\\ 0\\.006419423892902049\ \(0\)\
\-\ 2006\\:\\ 0\\.006419423892902049\ \(0\)\
\-\ staging\\:\\ 0\\.006419423892902049\ \(0\)\
\-\ axial\\:\\ 0\\.006359299807217396\ \(0\)\
\-\ collagen\\:\\ 0\\.006341948768429036\ \(0\)\
\-\ through\\:\\ 0\\.006328440725999657\ \(0\)\
\-\ hormone\\:\\ 0\\.006317114094412486\ \(0\)\
\-\ the\\:\\ 0\\.006308637502773016\ \(0\)\
\-\ treat\\:\\ 0\\.00629274364719977\ \(0\)\
\-\ a\\.\\:\\ 0\\.006245328204995239\ \(0\)\
\-\ which\\:\\ 0\\.006239157446841782\ \(0\)\
\-\ matrix\\:\\ 0\\.006222251833288068\ \(0\)\
\-\ however\\:\\ 0\\.00620434955827137\ \(0\)\
\-\ evaluating\\:\\ 0\\.00619957681019567\ \(0\)\
\-\ making\\:\\ 0\\.0061772894133778075\ \(0\)\
\-\ paget\\:\\ 0\\.0061772894133778075\ \(0\)\
\-\ produce\\:\\ 0\\.0061772894133778075\ \(0\)\
\-\ drugs\\:\\ 0\\.006155376612443804\ \(0\)\
\-\ shows\\:\\ 0\\.006126137417806724\ \(0\)\
\-\ to\\:\\ 0\\.0061248359750623845\ \(0\)\
\-\ at\\:\\ 0\\.006037878241625204\ \(0\)\
\-\ fracture\\:\\ 0\\.005875030848168914\ \(0\)\
\-\ 29\\:\\ 0\\.005813311078587883\ \(0\)\
\-\ these\\:\\ 0\\.005798812756083025\ \(0\)\
\-\ comparison\\:\\ 0\\.0057967021792692\ \(0\)\
\-\ 33\\:\\ 0\\.005780302202467557\ \(0\)\
\-\ each\\:\\ 0\\.005764105957358617\ \(0\)\
\-\ helpful\\:\\ 0\\.005764105957358617\ \(0\)\
\-\ workup\\:\\ 0\\.0057323048450715775\ \(0\)\
\-\ p\\:\\ 0\\.005716690515154086\ \(0\)\
\-\ advanced\\:\\ 0\\.005701260974545217\ \(0\)\
\-\ order\\:\\ 0\\.005583988175766939\ \(0\)\
\-\ develop\\:\\ 0\\.005556247108690948\ \(0\)\
\-\ d\\:\\ 0\\.005556247108690948\ \(0\)\
\-\ thus\\:\\ 0\\.005542594827247278\ \(0\)\
\-\ osteoarthritis\\:\\ 0\\.0055290840227680774\ \(0\)\
\-\ different\\:\\ 0\\.00551571179308465\ \(0\)\
\-\ metabolic\\:\\ 0\\.005502475324422306\ \(0\)\
\-\ left\\-sided\\:\\ 0\\.005489371887846684\ \(0\)\
\-\ consistent\\:\\ 0\\.00546361999695229\ \(0\)\
\-\ replacement\\:\\ 0\\.005438236668611637\ \(0\)\
\-\ plexus\\:\\ 0\\.005413401994595087\ \(0\)\
\-\ unusual\\:\\ 0\\.005389031547382371\ \(0\)\
\-\ rarely\\:\\ 0\\.00534161610517784\ \(0\)\
\-\ veins\\:\\ 0\\.0053300268647381455\ \(0\)\
\-\ states\\:\\ 0\\.005240844691485993\ \(0\)\
\-\ imaging\\:\\ 0\\.0052205314848907496\ \(0\)\
\-\ current\\:\\ 0\\.005219470754359948\ \(0\)\
\-\ recently\\:\\ 0\\.005198441573225811\ \(0\)\
\-\ a\\:\\ 0\\.005170792722537175\ \(0\)\
\-\ urinary\\:\\ 0\\.005157374210697296\ \(0\)\
\-\ incidence\\:\\ 0\\.005107794816187205\ \(0\)\
\-\ must\\:\\ 0\\.0050789276377293\ \(0\)\
\-\ l\\:\\ 0\\.0050789276377293\ \(0\)\
\-\ reaction\\:\\ 0\\.005060031930685536\ \(0\)\
\-\ r\\:\\ 0\\.005060031930685536\ \(0\)\
\-\ can\\:\\ 0\\.005054034817390012\ \(0\)\
\-\ j\\:\\ 0\\.005032192133461848\ \(0\)\
\-\ it\\:\\ 0\\.005008731120033942\ \(0\)\
\-\ surface\\:\\ 0\\.004917983451169819\ \(0\)\
\-\ until\\:\\ 0\\.004892990079451801\ \(0\)\
\-\ may\\:\\ 0\\.0048874272983001925\ \(0\)\
\-\ pathologic\\:\\ 0\\.0048765901026501576\ \(0\)\
\-\ 2\\:\\ 0\\.004798186431578999\ \(0\)\
\-\ via\\:\\ 0\\.00478229980072105\ \(0\)\
\-\ but\\:\\ 0\\.004752290224337778\ \(0\)\
\-\ site\\:\\ 0\\.004708620256701047\ \(0\)\
\-\ bones\\:\\ 0\\.004701476233539866\ \(0\)\
\-\ references\\:\\ 0\\.004632109824069899\ \(0\)\
\-\ related\\:\\ 0\\.004598763224604906\ \(0\)\
\-\ tissues\\:\\ 0\\.0045726867360694826\ \(0\)\
\-\ presents\\:\\ 0\\.004551875607582597\ \(0\)\
\-\ where\\:\\ 0\\.0045471215843245335\ \(0\)\
\-\ bladder\\:\\ 0\\.004522048100715814\ \(0\)\
\-\ treatment\\:\\ 0\\.004510083336638558\ \(0\)\
\-\ 25\\:\\ 0\\.004503554443620695\ \(0\)\
\-\ patient\\:\\ 0\\.004467233016513105\ \(0\)\
\-\ symptomatic\\:\\ 0\\.0044263147649207454\ \(0\)\
\-\ uptake\\:\\ 0\\.0044263147649207454\ \(0\)\
\-\ use\\:\\ 0\\.00440344082795737\ \(0\)\
\-\ necrosis\\:\\ 0\\.004397784502535469\ \(0\)\
\-\ unknown\\:\\ 0\\.004347952412809004\ \(0\)\
\-\ pleural\\:\\ 0\\.00432640182356362\ \(0\)\
\-\ thoracic\\:\\ 0\\.004294729473408412\ \(0\)\
\-\ 30\\:\\ 0\\.0042843407254955345\ \(0\)\
\-\ images\\:\\ 0\\.0042744821172082245\ \(0\)\
\-\ its\\:\\ 0\\.004204082716369806\ \(0\)\
\-\ has\\:\\ 0\\.004184354551484427\ \(0\)\
\-\ view\\:\\ 0\\.004179982566859894\ \(0\)\
\-\ metastasis\\:\\ 0\\.004170465875228066\ \(0\)\
\-\ throughout\\:\\ 0\\.004170465875228066\ \(0\)\
\-\ \\‚\\Ä\\ú\\:\\ 0\\.004161018145735541\ \(0\)\
\-\ \\‚\\Ä\\ù\\:\\ 0\\.00413769407174496\ \(0\)\
\-\ diagnosed\\:\\ 0\\.004096734233109525\ \(0\)\
\-\ typically\\:\\ 0\\.003932758500007787\ \(0\)\
\-\ location\\:\\ 0\\.003886189943812116\ \(0\)\
\-\ less\\:\\ 0\\.003773063890903106\ \(0\)\
\-\ 10\\:\\ 0\\.003755703035654381\ \(0\)\
\-\ and\\:\\ 0\\.00375507704265384\ \(0\)\
\-\ left\\:\\ 0\\.0037396555512630306\ \(0\)\
\-\ by\\:\\ 0\\.003710223998030964\ \(0\)\
\-\ white\\:\\ 0\\.0036950511247875067\ \(0\)\
\-\ back\\:\\ 0\\.0036754450265286532\ \(0\)\
\-\ radiation\\:\\ 0\\.0036561293996901388\ \(0\)\
\-\ radiograph\\:\\ 0\\.0035488248421399774\ \(0\)\
\-\ between\\:\\ 0\\.0035312849233692877\ \(0\)\
\-\ radiographs\\:\\ 0\\.003528384408346979\ \(0\)\
\-\ known\\:\\ 0\\.003525490331765084\ \(0\)\
\-\ onset\\:\\ 0\\.003516846448403064\ \(0\)\
\-\ found\\:\\ 0\\.00351111553383587\ \(0\)\
\-\ will\\:\\ 0\\.0034856336615112673\ \(0\)\
\-\ usually\\:\\ 0\\.0033832180624077694\ \(0\)\
\-\ as\\:\\ 0\\.0033704758954214544\ \(0\)\
\-\ years\\:\\ 0\\.003271503438094501\ \(0\)\
\-\ 5\\:\\ 0\\.003259661567723811\ \(0\)\
\-\ lung\\:\\ 0\\.003227065345813228\ \(0\)\
\-\ level\\:\\ 0\\.003211067832655713\ \(0\)\
\-\ his\\:\\ 0\\.003211067832655713\ \(0\)\
\-\ when\\:\\ 0\\.0031907838821590684\ \(0\)\
\-\ of\\:\\ 0\\.0031898041939475317\ \(0\)\
\-\ lymphoma\\:\\ 0\\.0031840920917724715\ \(0\)\
\-\ ct\\:\\ 0\\.003116828300891898\ \(0\)\
\-\ are\\:\\ 0\\.003037480762789053\ \(0\)\
\-\ cell\\:\\ 0\\.0030094403019315335\ \(0\)\
\-\ therapy\\:\\ 0\\.0029786711815392606\ \(0\)\
\-\ \\:\\:\\ 0\\.0029472615801581876\ \(0\)\
\-\ common\\:\\ 0\\.0029156026231504525\ \(0\)\
\-\ patients\\:\\ 0\\.002883408864883997\ \(0\)\
\-\ over\\:\\ 0\\.002836561395228113\ \(0\)\
\-\ acute\\:\\ 0\\.0027508205073096415\ \(0\)\
\-\ increased\\:\\ 0\\.002725534265710112\ \(0\)\
\-\ pain\\:\\ 0\\.0027212729270684084\ \(0\)\
\-\ man\\:\\ 0\\.0026348524681747056\ \(0\)\
\-\ associated\\:\\ 0\\.002629025504442897\ \(0\)\
\-\ 3\\:\\ 0\\.002608833802746466\ \(0\)\
\-\ present\\:\\ 0\\.0025163086752694663\ \(0\)\
\-\ this\\:\\ 0\\.0025062248065557576\ \(0\)\
\-\ multiple\\:\\ 0\\.002346552807665279\ \(0\)\
\-\ after\\:\\ 0\\.002305086313701698\ \(0\)\
\-\ lesion\\:\\ 0\\.002269302771838924\ \(0\)\
\-\ male\\:\\ 0\\.0020146095669980094\ \(0\)\
\-\ that\\:\\ 0\\.0019243555783035507\ \(0\)\
\-\ normal\\:\\ 0\\.0017465612185125175\ \(0\)\
\-\ there\\:\\ 0\\.0016580385351564388\ \(0\)\
\-\ \\.\\:\\ 0\\.0016199266798006776\ \(0\)\
\-\ not\\:\\ 0\\.001609933079194179\ \(0\)\
\-\ mass\\:\\ 0\\.001549492838262796\ \(0\)\
\-\ an\\:\\ 0\\.0015406321568249412\ \(0\)\
\-\ with\\:\\ 0\\.001372930358290753\ \(0\)\
\-\ or\\:\\ 0\\.0013057662959109616\ \(0\)\
